glp 1 vs metformin vs. GLP-1 Receptor Agonists: Which Diabetes Medication Is Right for You? GLP-1 vs. Metformin… let's simplify

Laboratory data were extracted at two different points: throughout the baseline period and at the point closest to the index date, since the long baseline period may not reflect the actual value at time of drug initiation

In August 2024, Metsera, a newly launched clinical-stage biopharmaceutical company, emerged with a significant US$ 290 million in funding to develop innovative treatments for obesity and metabolic diseases, particularly focusing on GLP-1 receptor agonists

Tirzepatide users report higher rates of gastrointestinal disturbance, likely due to the dual receptor mechanism

Yu JH, Park SY, Lee DY, Kim NH, Seo JA

Global Weight-Loss Deal Activity in 2025 H1: Partnerships and New Drug Investments In H1 2025, the weight-loss sector and metabolic diseases saw a flurry of dealmaking